이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

RRMM의 신규 제제와 조합된 이사툭시맙 - 마스터 프로토콜

2026년 11월 16일 업데이트: Sanofi

재발성 또는 불응성 다발성 골수종(RRMM)에서 포말리도마이드 및 덱사메타손을 병용한 이사툭시맙과 비교하여 신규 제제와 덱사메타손을 병용하거나 병용하지 않은 이사툭시맙을 평가하는 1-2상 UMBRELLA 시험 - 마스터 프로토콜

The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.

연구 개요

상세 설명

Participants will continue study treatment until disease progression, death, unacceptable toxicity, participant request to stop treatment, Investigator decision, or study termination by the Sponsor i.e., up to Aapproximately 28 months.

연구 유형

중재적

등록 (추정된)

258

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Trial Transparency email recommended (Toll free number for US & Canada)
  • 전화번호: option 6 800-633-1610
  • 이메일: contact-us@sanofi.com

연구 장소

      • Athens, 그리스, 115 28
        • 모병
        • Investigational Site Number : 3000001
      • Athens, 그리스, 106 76
        • 모병
        • Investigational Site Number : 3000002
      • Oslo, 노르웨이, 0450
        • 모병
        • Investigational Site Number : 5780001
    • Seoul-teukbyeolsi
      • Seoul, Seoul-teukbyeolsi, 대한민국, 03722
        • 모병
        • Investigational Site Number : 4100004
      • Seoul, Seoul-teukbyeolsi, 대한민국, 06351
        • 모병
        • Investigational Site Number : 4100002
      • Seoul, Seoul-teukbyeolsi, 대한민국, 03080
        • 모병
        • Investigational Site Number : 4100001
      • Seoul, Seoul-teukbyeolsi, 대한민국, 06591
        • 모병
        • Investigational Site Number : 4100003
      • Frankfurt, 독일, 60590
        • 모병
        • Investigational Site Number : 2760006
      • Lübeck, 독일, 23562
        • 모병
        • Investigational Site Number : 2760008
    • Alabama
      • Birmingham, Alabama, 미국, 35233
        • 완전한
        • University of Alabama at Birmingham- Site Number : 8400001
    • Georgia
      • Atlanta, Georgia, 미국, 30322
        • 모병
        • Winship Cancer Institute of Emory University- Site Number : 8400010
    • Illinois
      • Chicago, Illinois, 미국, 60612
        • 완전한
        • University of Illinois-Chicago - College of Medicine- Site Number : 8400007
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109
        • 모병
        • University of Michigan Health System - Ann Arbor- Site Number : 8400004
    • New York
      • Buffalo, New York, 미국, 14263
        • 모병
        • Roswell Park Cancer Institute- Site Number : 8400008
    • Ohio
      • Columbus, Ohio, 미국, 43210
        • 모병
        • The Ohio State University- Site Number : 8400012
      • Jerusalem, 이스라엘, 9112001
        • 모병
        • Investigational Site Number : 3760002
      • Ramat Gan, 이스라엘, 5262100
        • 모병
        • Investigational Site Number : 3760003
      • Tel Aviv, 이스라엘, 6423906
        • 모병
        • Investigational Site Number : 3760001
    • Reggio Emilia
      • Meldola, Reggio Emilia, 이탈리아, 47014
        • 모병
        • Investigational Site Number : 3800001
    • Puerto Rico
      • Hato Rey, Puerto Rico, 푸에르토 리코, 00917
        • 완전한
        • Puerto Rico Medical Research Center- Site Number : 8400005
      • Lille, 프랑스, 59037
        • 모병
        • Investigational Site Number : 2500002
      • Nantes, 프랑스, 44093
        • 모병
        • Investigational Site Number : 2500001
      • Paris, 프랑스, 75013
        • 모병
        • Investigational Site Number : 2500003
      • Paris, 프랑스, 75015
        • 모병
        • Investigational Site Number : 2500004
    • New South Wales
      • Wollongong, New South Wales, 호주, 2500
        • 모병
        • Investigational Site Number : 0360006
    • Victoria
      • Heidelberg, Victoria, 호주, 3084
        • 완전한
        • Investigational Site Number : 0360003
      • Melbourne, Victoria, 호주, 3065
        • 모병
        • Investigational Site Number : 0360002
      • Richmond, Victoria, 호주, 3121
        • 모병
        • Investigational Site Number : 0360001

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Participant must be 18 years of age inclusive or older.

  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

  • Participants with relapsed or refractory MM who have received at least 2 prior lines of therapy for MM, including PIs and IMiDs (eg, Induction regimen with autologous stem cell transplant followed by maintenance is considered one line).

  • RRMM with measurable disease:

    • Serum M protein ≥0.5 g/dL measured using serum protein immunoelectrophoresis and/or
    • Urine M protein ≥200 mg/24 hours measured using urine protein immunoelectrophoresis and/or
    • Serum free light chain (sFLC) MM without measurable M protein in serum or urine per previous criteria (serum Ig free light chain ≥10 mg/dL and abnormal serum Ig kappa lambda free light chain ratio <0.26 or >1.65).
  • Men or woman or childbearing potential should agree to use contraception.

  • Substudy 01, 06: Anti-CD38 therapy naïve or prior exposure to such drugs with a wash out of at least 12 months after the last dose. "Exposure" is defined as at least 2 cycles of therapy.

  • Substudies 02, 03: Anti-CD38 therapy naïve or prior exposure to such drugs without being refractory but with a wash out of at least 6 months after the last dose. "Refractory" is defined as progressing within 60 days of last dose of anti-CD38 targeting therapy.

  • Substudy 04: Anti-CD38 and anti-B cell maturation antigen (BCMA) therapy (if available) prior exposed participants with RRMM. For anti-CD38, "Exposure" is defined as at least 2 cycles of therapy. For anti-BCMA therapy if available, exposure is defined by at least 2 cycles of therapy.

  • Substudy 05: Participants with RRMM with at least 2 cycles of prior exposure to anti-CD38 therapy. For participants to whom BCMA targeted therapy is available (ie, approved in their region and can be reimbursed), at least 2 cycles of prior exposure to a BCMA targeted agent is mandatory.

Exclusion Criteria:

  • Primary systemic amyloid light chain amyloidosis, plasma cell leukemia, monoclonal gammopathy of undetermined significance, or smoldering myeloma.
  • Uncontrolled infection within 14 days prior to first study intervention administration.
  • Clinically significant cardiac (including valvular) or vascular disease within 3 months prior to first study intervention administration., eg, myocardial infarction, unstable angina, coronary (eg, coronary artery bypass graft, percutaneous coronary intervention) or peripheral artery revascularization, left ventricular ejection fraction <40%, heart failure New York Heart Association Classes III and IV, stroke, transient ischemic attack, pulmonary embolism, other thromboembolic event, or cardiac arrhythmia (Grade 3 or higher by NCI CTCAE Version 5.0).
  • Known acquired immunodeficiency syndrome-related illness or known human immunodeficiency virus (HIV) disease requiring antiviral treatment or active hepatitis A.
  • Uncontrolled or active hepatitis B virus (HBV) infection.
  • Active hepatitis C virus (HCV) infection.
  • Any of the following within 3 months prior to first study intervention administration: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease.
  • Second malignancy other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma, unless they are successfully treated with curative intent for more than 3 years before first study intervention administration.
  • Any anti-MM drug treatment within 14 days before first study intervention administration, including dexamethasone.
  • Participants with a contraindication to treatment.
  • Vaccination with a live vaccine 4 weeks before the start of the study.
  • Seasonal flu and COVID-19 vaccines that do not contain live virus are permitted.
  • Hemoglobin <8 g/dL.
  • Platelets <50 × 10^9/L.
  • Absolute neutrophil count <1.0 × 10^9/L.
  • Creatinine clearance <30 mL/min/1.73m2.
  • Total bilirubin >1.5 × ULN, except for known Gilbert syndrome in which direct bilirubin should be ≤2.5 × ULN.
  • Aspartate aminotransferase and/or alanine aminotransferase >3 × ULN.
  • Patients with grade 3 or 4 hypercalcemia.

Substudy 01:

-Malabsorption syndrome or any condition that can significantly impact the absorption of pomalidomide.

Substudy 02:

  • History of resected/ablated basal or squamous cell carcinoma (SCC) of the skin or carcinoma in situ of the cervix, or other local tumors, even if considered cured by local treatment.
  • Therapeutic doses of anticoagulants or antiplatelet agents within 7 days prior to the first dose of SAR439459.
  • Prothrombin time or INR >1.5 × upper limit of normal (ULN).

Substudy 03:

  • Current corneal epithelial disease except mild punctate keratopathy.
  • Patients who have received prior therapy with belantamab mafodotin.

Substudy 04:

  • Central nervous system or leptomeningeal disease.
  • Medical history of seizure.
  • Participants currently receiving hepatically metabolized narrow therapeutic index drugs (eg, digoxin, warfarin) if cannot be closely monitored.
  • Active, known, or suspected autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs), except controlled by replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc). The following are not exclusionary: vitiligo, childhood asthma that has resolved, psoriasis that does not require systemic treatment.
  • Prior allogeneic hematopoietic stem cell transplant (allo-HSCT).

Substudy 05:

- Participant unable to swallow tablets.

Substudy 06:

  • History of active autoimmune disorders.
  • History of autoimmune hemolytic anemia or autoimmune. thrombocytopenia.
  • Active graft versus host disease (GVHD) or ongoing immunosuppression for GVHD.
  • Prior allogenic hematopoietic stem cell transplant (allo-HSCT).
  • Patient with chronic active EBV infection.
  • Patients with known history of HLH.
  • Hemoglobin < 9 g/dL.
  • Prior therapy with any anti-CD47 or anti signal regulatory protein alpha agent.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Control Arm: isatuximab + pomalidomide + dexamethasone (Substudy 01)
  • Isatuximab, intravenous (IV) doseweekly (QW) × 4 weeks (Cycle 1), followed by every two weeks (Q2W) (subsequent cycles).
  • Pomalidomide dose by mouth daily Day 1 to Day 21.
  • Dexamethasone dose by mouth QW.

Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion

다른 이름들:
  • SAR650984
  • 사클리사®

Pharmaceutical form: Tablet; Route of administration: Oral

Pharmaceutical form: Capsule; Route of administration: Oral

다른 이름들:
  • 포말리스트®
실험적: isatuximab + SAR439459 + dexamethasone (Substudy 02)

SAR439459 in combination with isatuximab and dexamethasone

Part 1:

2 dose levels (DLs) of IV SAR439459:

  • DL1 SAR439459 dose Q2W.
  • DL2 SAR439459 dose Q2W.
  • Isatuximab dose IV QW × 5 weeks (Cycle 1), followed by Q2W administrations (subsequent cycles).
  • Dexamethasone fixed dose and schedule: QW by mouth In Cycle 1, the first administration of SAR439459 (Day 1) will precede isatuximab by 1 week (first dose of isatuximab will be at Cycle 1 Day 8).

Part 2:

  • SAR439459 IV dose Q2W.
  • Isatuximab IV dose QW × 5 weeks (Cycle 1), followed by Q2W administrations (subsequent cycles).
  • Dexamethasone fixed dose and schedule: QW by mouth. In Cycle 1, the first administration of SAR439459 (Day 1) will precede isatuximab by 1 week (first dose of isatuximab will be at Cycle 1 Day 8).

Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion

다른 이름들:
  • SAR650984
  • 사클리사®

Pharmaceutical form: Tablet; Route of administration: Oral

Pharmaceutical form: Solution for injection; Route of administration: Intravenous

실험적: isatuximab + dexamethasone + belantamab mafodotin (Substudy 03)

Belantamab mafodotin in combination with isatuximab and dexamethasone

Part 1:

1 DL of IV belantamab mafodotin in Part 1 and de-escalation dose DL-1:

  • DL1 belantamab mafodotin IV dose QW4 or de-escalation dose DL-1 QW8
  • Isatuximab dose, IV QW × 4 weeks (Cycle 1), followed by Q2W (subsequent cycles).
  • Dexamethasone fixed dose and schedule: QW by mouth.

Part 2:

  • Isatuximab IV dose QW × 4 weeks (Cycle 1), followed by Q2W (subsequent cycles).
  • Belantamab mafodotin IV dose Q4W or Q8W
  • Dexamethasone fixed dose and schedule: QW by mouth.

Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion

다른 이름들:
  • SAR650984
  • 사클리사®

Pharmaceutical form: Tablet; Route of administration: Oral

Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

다른 이름들:
  • 블렌렙®
실험적: Isatuximab + pegenzileukin (Substudy 04)

Pegenzileukin in combination with isatuximab

Part 1- dose escalation:

  • Up to 3 DLs of IV pegenzileukin are planned to be evaluated:

    • DL1 will explore pegenzileukin at Q2W.
    • DL2 will explore pegenzileukin at Q2W.
    • DL3 will explore pegenzileukin at Q2W.
  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles).

Part 1 - dose optimization:

  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles).
  • Pegenzileukin at potential doses (DL A and DL B) Q2W.

Part 2 (dose expansion):

  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles).
  • Pegenzileukin IV dose Q2W.

Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion

다른 이름들:
  • SAR650984
  • 사클리사®

Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

다른 이름들:
  • SAR444245
실험적: Experimental: Isatuximab + Dexamethasone + Belumosudil (Substudy 05)

Isatuximab in combination with belumosudil and dexamethasone Part 1- dose escalation: During the first cycle, belumosudil will be evaluated in monotherapy during 2 to 4 weeks, then isatuximab and dexamethasone will be added, and continued for the subsequent cycles.

  • Belumosudil by mouth at Dose Level (DL) 1, DL2, DL3, and DL4
  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)
  • Dexamethasone fixed dose and schedule: QW by mouth

Part 1- dose optimization:

  • Belumosudil at potential doses (DL A and DL B), daily by mouth
  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)
  • Dexamethasone fixed dose and schedule: QW by mouth

Part 2- dose expansion:

  • Belumosudil dose daily, by mouth
  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)
  • Dexamethasone fixed dose and schedule: QW by mouth

Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion

다른 이름들:
  • SAR650984
  • 사클리사®

Pharmaceutical form: Tablet; Route of administration: Oral

Pharmaceutical form: tablet; route of administration: oral

다른 이름들:
  • 레즈락
  • SAR445761,
실험적: Isatuximab + evorpacept + dexamethasone (Substudy 06)

Isatuximab in combination with evorpacept and dexamethasone

Part 1- dose escalation:

  • Evorpacept IV dose Q2W
  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)
  • Dexamethasone fixed dose and schedule: QW by mouth Part 1- dose optimization
  • Evorpacept IV at potential doses (DL A and DL B), Q2W
  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)
  • Dexamethasone fixed dose and schedule: QW by mouth

Part 2- dose expansion:

  • Evorpacept IV dose Q2W
  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)
  • Dexamethasone fixed dose and schedule: QW by mouth

Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion

다른 이름들:
  • SAR650984
  • 사클리사®

Pharmaceutical form: Tablet; Route of administration: Oral

Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

다른 이름들:
  • ALX148

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Part 1 (dose finding, experimental substudies): Determination of recommended dose of novel agents in combination with isatuximab
기간: Through the end of cycle 1 (approximately 6 weeks)

Determination or confirmation of the dose will be based on: safety and tolerability in terms of TEAEs/SAEs, dose-limiting toxicity occurrence, and laboratory parameters available information on PK (if appropriate) and biomarkers.

Through the end of cycle 1 (approximately 6 weeks)
Part 2 (expansion, controlled experimental substudies): VGPR Rate (Rate of Very Good Partial Response Rate or Better)
기간: Up to approximately 28 months after the First patient in or scheduled assessment

VGPR or better rate is defined as the percentage of participants with a VGPR or better as defined by the 2016 IMWG response criteria, assessed by Investigator based on central laboratory values and local imaging.

Up to approximately 28 months after the First patient in or scheduled assessment
Part 2 (expansion, independent experimental substudies): Overall Response Rate (ORR) in independent experimental substudies
기간: Up to approximately 28 months after the First patient in or scheduled assessment

ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), VGPR, or partial response (PR), according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging.

Up to approximately 28 months after the First patient in or scheduled assessment

2차 결과 측정

결과 측정
측정값 설명
기간
신규 제제 (실험 팔) 및 이사 툭시 맙 (Ctrough)의 농도
기간: 사이클 1 동안 다중 시계. 사이클은 28 일입니다.
사이클 1 동안 다중 시계. 사이클은 28 일입니다.
Belumosudil에 대한 첫 번째 주입 (CMAX) 후 관찰 된 최대 농도 - Substudy 05
기간: 사이클 1 동안 다중 시계. 사이클은 28 일입니다.
사이클 1 동안 다중 시계. 사이클은 28 일입니다.
Belumosudil의 Cmax (Tmax)에 도달 할 시간 -Substudy 05
기간: 사이클 1 동안 다중 시계. 사이클은 28 일입니다.
사이클 1 동안 다중 시계. 사이클은 28 일입니다.
Belumosudil -Substudy 05에 대해 0 내지 8H (AUC0-8H)의 사다리꼴 방법을 사용하여 계산 된 농도 대 시간 곡선에 따른 영역
기간: 사이클 1 동안 다중 시계. 사이클은 28 일입니다.
사이클 1 동안 다중 시계. 사이클은 28 일입니다.
Evorpacept에 대한 첫 번째 주입 (CMAX) 후 관찰 된 최대 농도 -Substudy 06
기간: 사이클 1 동안 다중 시계. 사이클은 28 일입니다.
사이클 1 동안 다중 시계. 사이클은 28 일입니다.
Evorpacept의 Cmax (Tmax)에 도달 할 시간 -Substudy 06
기간: 사이클 1 동안 다중 시계. 사이클은 28 일입니다.
사이클 1 동안 다중 시계. 사이클은 28 일입니다.
Evorpacept (AUC0-T)에 대한 투약 간격에 대한 사다리꼴 방법을 사용하여 계산 된 농도 대 시간 곡선에 따른 영역- Substudy 06
기간: 사이클 1 동안 다중 시계. 사이클은 28 일입니다.
사이클 1 동안 다중 시계. 사이클은 28 일입니다.
Part 1 (dose finding, experimental substudies): ORR
기간: Up to approximately 28 months after the First patient in or scheduled assessment

ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), VGPR, or partial response (PR), according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging.

Up to approximately 28 months after the First patient in or scheduled assessment
Part 2 (expansion, controlled experimental substudies): ORR
기간: Up to approximately 28 months after the First patient in or scheduled assessment

ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), VGPR, or partial response (PR), according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging.

Up to approximately 28 months after the First patient in or scheduled assessment
Part 1 (dose finding, experimental substudies): VGPR or better
기간: Up to approximately 28 months after the First patient in or scheduled assessment

VGPR or better rate is defined as the percentage of participants with a VGPR or better as defined by the 2016 IMWG response criteria, assessed by Investigator based on central laboratory values and local imaging.

Up to approximately 28 months after the First patient in or scheduled assessment
Part 2 (expansion, independent experimental substudies): VGPR or better
기간: Up to approximately 28 months after the First patient in or scheduled assessment

VGPR or better rate is defined as the percentage of participants with a VGPR or better as defined by the 2016 IMWG response criteria, assessed by Investigator based on central laboratory values and local imaging.

Up to approximately 28 months after the First patient in or scheduled assessment
Clinical benefit rate (CBR) in each treatment arm
기간: Up to approximately 28 months after the First patient in or scheduled assessment

CBR, defined as the proportion of participants with sCR, CR, VGPR, PR, or minimal response, according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging.

Up to approximately 28 months after the First patient in or scheduled assessment
Duration of Response (DOR) in each treatment arm
기간: Up to approximately 28 months after the First patient in or scheduled assessment

DOR, defined as the time from the date of the first response that is subsequently confirmed for patients achieving PR or better to the date of first documented PD or death, whichever happens first.

Up to approximately 28 months after the First patient in or scheduled assessment
Time to First Response (TT1R) in each treatment arm
기간: Up to approximately 28 months after the First patient in or scheduled assessment

TT1R, defined as the time from the date of first treatment to the date of first response (PR or better) that is subsequently confirmed.

Up to approximately 28 months after the First patient in or scheduled assessment
Time to Best Response (TTBR) in each treatment arm
기간: Up to approximately 28 months after the First patient in or scheduled assessment

TTBR, defined as the time from the date of first treatment to the date of first occurrence of best overall response (PR or better) that is subsequently confirmed.

Up to approximately 28 months after the First patient in or scheduled assessment
Number of participants with treatment emergent adverse events and serious adverse events in each treatment arm
기간: Up to approximately 28 months after the First patient in or scheduled assessment

Safety and tolerability assessed in terms of adverse events/SAEs, including second primary malignancies, laboratory parameters, vital signs, and findings from physical examination.

Up to approximately 28 months after the First patient in or scheduled assessment
Progression-free survival (PFS) in each treatment arm
기간: Up to approximately 28 months after the First patient in or scheduled assessment

PFS is defined as the time from the date of first treatment to disease progression based on the Investigator assessment according to 2016 IMWG criteria or death from any cause, whichever happens first.

Up to approximately 28 months after the First patient in or scheduled assessment
Overall Survival (OS) in each treatment arm
기간: Up to approximately 28 months after the First patient in or scheduled assessment

OS is defined as the time from the date of first treatment to death from any cause.

Up to approximately 28 months after the First patient in or scheduled assessment
Immunogenicity of isatuximab and novel agents
기간: Multiple timepoints up to approximately 28 months after the First patient in or scheduled assessment

Incidence of anti-drug antibodies (ADAs) for novel agents (experimental arms) and isatuximab.

Multiple timepoints up to approximately 28 months after the First patient in or scheduled assessment
Disease-specific HRQL will be assessed using the European Organization for Research and Treatment of Cancer (EORTC) core quality of life questionnaire (QLQ-C30)
기간: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.

The EORTC QLQ-C30 will be used to assess cancer-specific HRQL, disease and treatment-related symptoms and impact of symptoms. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies).

On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
Disease- and treatment-related quality of life will be assessed using the EORTC multiple myeloma module (QLQ-MY20) questionnaire
기간: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.

The EORTC QLQ-MY20 will be used to measure myeloma-specific HRQL, disease and treatment-related symptoms and impact of symptoms. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies).

On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
Global impact of side effects will be assessed using the Functional Assessment of Cancer Therapy (FACT-G) (GP5)
기간: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.

A single item from the FACT-G GP5 will be used to assess the global impact of side effects. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies).

On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
Estimate/Confirm established clinically meaningful change scores for clinical outcome assessments (COAs)/domain scores using the Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) scales
기간: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.

Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) scales will be utilized as anchors to estimate/confirm established clinically meaningful change scores for clinical outcome assessments (COAs)/domain scores. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies).

On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
The intensity of skeletal-related events (SRE)- related bone pain will be assessed using the skeletal-related bone pain numeric rating scale (SRE-BP-NRS) for control and experimental arms -Substudy 02
기간: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.

The SRE-BP-NRS) will be used to assess the intensity of SRE-related bone pain (on average and at its worst) for control arm only

On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
SRE Incidence for control and experimental arms- Substudy 02
기간: Continuous throughout study assessment (up to approximately 28 months)

SRE incidence, defined as the proportion of participants who experienced pathological fracture, radiation to bone, spinal cord compression, or surgery to bone as a first bone event.

Continuous throughout study assessment (up to approximately 28 months)
Time to First Occurrence of SRE Assessment for control and experimental arms (Substudy 02)
기간: Continuous throughout study assessment (up to approximately 28 months)

Time to first occurrence of SRE is defined as time from the date of randomization to the occurrence of first SRE.

Continuous throughout study assessment (up to approximately 28 months)
Assessment of Health care resource utilization related with SREs for control and experimental arms -Substudy 02
기간: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at End of treatment and at first follow-up visit. The cycle is 28 days.

The Health Care Resource Use-SREs questionnaire (HCRU-SREs) will be used to assess the use of health care resources associated with these events.

On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at End of treatment and at first follow-up visit. The cycle is 28 days.
To assess patient-reported visual functioning for experimental arm only -Substudy 03
기간: On Day1 Cycle 1, End of treatment and at first follow-up visit. The cycle is 28 days.

An NEI VFQ-25 will be used to assess patient-reported visual functioning.

On Day1 Cycle 1, End of treatment and at first follow-up visit. The cycle is 28 days.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Clinical Sciences & Operations, Sanofi

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 1월 25일

기본 완료 (추정된)

2027년 9월 13일

연구 완료 (추정된)

2028년 4월 20일

연구 등록 날짜

최초 제출

2020년 10월 20일

QC 기준을 충족하는 최초 제출

2020년 11월 20일

처음 게시됨 (실제)

2020년 11월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 17일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 16일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • ACT16482
  • 2020-003024-16 (EudraCT 번호)
  • U1111-1244-2598 (레지스트리 식별자: ICTRP)
  • 2024-514988-25 (레지스트리 식별자: CTIS)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다